In this second installment of MedPage Today's virtual roundtable series on pediatric low-grade glioma, moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, is joined once ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on pediatric low-grade glioma. Moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, ...

Low-grade brain tumors known as IDH-mutant gliomas CNS WHO grade 2 are life-threatening in spite of their slow growth.

These tumors are less likely to spread to surrounding tissues than higher-grade tumors, so they often have better outcomes. In the past, pediatric gliomas were classified into low-grade and high-grade ...

There are no evidence-based guidelines to direct the treatment of patients with low-grade glioma, and it remains unclear whether early treatment has an impact on outcome. To compare the long-term ...

If your child has been diagnosed with a pediatric low-grade glioma (pLGG), you may be wondering where, exactly, you should go for medical care. For starters, you’ll want to look for a treatment center ...

Diffuse low-grade gliomas include oligodendrogliomas and astrocytomas. The recent 2016 WHO classification has now updated the definition of these tumors to include molecular characterization, ...

Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ...

New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months ...

Ojemda treatment for certain patients with pediatric low-grade glioma is “well-tolerated” and may be safer than traditional options, an expert told CURE®. The recent accelerated Food and Drug ...

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas. The randomized phase 3 ...